News We’re Watching: Expiring Guidance Documents; Multi-Cancer Diagnostic Meeting Set; 510(k)s For BD And Smileyscope

This week, the US FDA announced that several pandemic-era guidance documents are no longer in effect; an FDA advisory committee meeting on multi-cancer detection (MCD) diagnostics was scheduled; and both a needle-free blood collection device and the first VR treatment for pain and anxiety landed FDA clearances.

Regulatory News We're Watching
• Source: Shutterstock

The first round of pandemic-era guidance documents to be retired after the May ending of the public health emergency are no longer in effect, the US Food and Drug Administration announced on 8 November.

The 16 policies being put to bed largely allowed enforcement discretion for a range of products that were in high demand during the pandemic, such as imaging systems, digital health devices to treat psychiatric conditions, face shields, infusion pumps, ventilators and accessories, as well as sterilizers and air purifiers. A full list is in the March guidance document, “

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation